# Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance

> **NCT00748098** · PHASE3 · COMPLETED · sponsor: **XenoPort, Inc.** · enrollment: 136 (actual)

## Conditions studied

- Restless Legs Syndrome
- Restless Legs Syndrome (RLS)

## Interventions

- **DRUG:** GSK1838262 Extended Release Tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00748098
- **Lead sponsor:** XenoPort, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2013-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00748098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00748098, "Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00748098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*